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Abstract.  Type 13 transforming growth factor (TGFI3) 
has been shown to be both a  positive and negative 
regulator of cellular proliferation and differentiation. 
The effects of TGFI3 also are cell-type specific and 
appear to be modulated by other growth factors. In the 
present study, we examined the potential of TGFI3 for 
control of myogenic differentiation. In mouse C-2 myo- 
blasts, TGFfl inhibited fusion and prevented expression 
of the muscle-specific gene products,  creatine kinase 
and acetylcholine receptor.  Differentiation of the non- 
fusing muscle cell line, BC3H1, was also inhibited by 
TGFI3 in a dose-dependent manner (IDs0 ~0.5 ng/ml). 
TGFI3 was not mitogenic for either muscle cell line, 
indicating that its inhibitory effects do not require 
cell proliferation. Inhibition of differentiation required 
the continual presence of TGFI3 in the culture media. 
Removal of TGFI3 led to rapid appearance of muscle 
proteins, which indicates that intracellular signals gen- 
erated by TGFfl are highly transient and require con- 
tinuous occupancy of the TGFI~ receptor.  Northern 
blot hybridization analysis using a muscle creatine ki- 
nase cDNA probe indicated that TGFI3 inhibited 
differentiation at the level of muscle-specific mRNA 
accumulation. These results provide the first demon- 
stration that TGFI3 is a potent regulator of myogenic 
differentiation and suggest that TGFI3 may play an im- 
portant role in the control of tissue-specific gene ex- 
pression during development. 
T 
YPE I~ transforming growth factor (TGFI3)  j is a poly- 
peptide homodimer of total Mr 25,000  that is abun- 
dant in platelets and is also present in a wide variety 
of tissues as well as in transformed cells (1, 2, 19, 20, 31, 37). 
TGFfl was first discovered by its ability to induce transforma- 
tion in normal cells (31). The cellular actions of TGFI3 are 
highly cell type specific and have been reported to be modu- 
lated by other growth factors present in serum (20, 21, 31, 32, 
37). The pleiotropic effects of TGFI3 include induction of an- 
chorage-independent growth in mesenchymal cells (32), in- 
hibition of adipocyte differentiation (11), induction of colla- 
gen and fibronectin synthesis (12), inhibition of  epithelial cell 
proliferation, and stimulation of epithelial cell differentiation 
(22).  In aortic smooth muscle cells, TGFI3 also acts by in- 
hibiting proliferation of subconfluent monolayer cultures, 
whereas it synergizes with mitogens to stimulate growth in 
soft agar (2).  The physiological role of this growth factor in 
the control of  cellular proliferation and differentiation  as well 
as  the  mechanisms whereby TGFI3 elicits  its  cellular re- 
sponses remain to be determined. 
The process of myogenesis involves withdrawal of prolifer- 
ating myoblasts out of the cell cycle, their subsequent fusion 
to form multi-nucleated myotubes, and the coordinate induc- 
1. Abbreviations used in this paper: ACh, acetylcholine; GAPDH, glycer- 
aldehyde-3-phosphate  dehydrogenase; MCK, muscle isoenzyme of creatine 
kinase; TGF13, type 13 transforming growth factor. 
tion of a battery of muscle-specific gene products (23-25). 
Because  activation of muscle-specific gene  expression  is 
coupled to cell cycle withdrawal rather than to fusion, a great 
deal of interest has focused on the role of growth factors in 
the control of muscle differentiation (4, 6, 7, 9,  10,  13,  14, 
16-18, 24, 25, 27-30, 35).  The majority of studies on regula- 
tion of myogenesis by mitogens have used fetal calf serum 
(FCS) as a crude source of mitogenic activity. With the ex- 
ception of fibroblast growth factor, which has been shown to 
inhibit muscle differentiation in a manner similar to serum 
(9,  10, 13, 14,  17, 18, 35), little is known of the identities or 
mechanisms of action of growth factors that regulate myo- 
genesis. 
Because of the diverse actions of TGF~, we examined the 
possible involvement of this growth factor in the control of 
myoblast proliferation and differentiation, using the C-2 and 
BC3H1 cell lines. These cell lines have been shown to ex- 
hibit properties of skeletal muscle and smooth muscle, re- 
spectively,  after differentiation in media without mitogens 
(27-29,  34,  36, 38).  In fusion-promoting media containing 
TGFI3, C-2 cells withdrew from the cell cycle but failed to 
fuse or differentiate as defined by expression of muscle crea- 
tine kinase and nicotinic acetylcholine (ACh) receptor. Sim- 
ilarly, in BC3H1 cells, TGFI~ delayed the onset of differen- 
tiation and inhibited muscle-specific mRNA accumulation. 
TGFfl was not mitogenic for either cell line, which indicates 
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ary consequence of cell proliferation.  These data demon- 
strate that TGFI3 is a unique regulator of myogenic differenti- 
ation and suggest that TGFI3 may play an important role in 
the control of tissue-specific gene expression during early 
development. 
Materials and Methods 
Cell Culture 
The BC3H1 mouse muscle cell line (34)  was grown in DME containing 
20%  FCS (Hazelton Research Products, Denver, PA) as described previ- 
ously (27). To initiate differentiation, media containing 20% serum was re- 
moved and replaced with media containing 0.5 % serum. 
The C-2 mouse muscle cell line (38) was grown in DME containing 20% 
FCS,  100  t~g/ml  L-glutamine,  penicillin  (100 U/ml),  and  streptomycin 
(100 ~tg/ml). To initiate fusion, cultures were transferred to DME containing 
10 gg/ml insulin, 5  gg/ml transferrin. 
TGFI3 (R & D Products, Minneapolis, MN) was resuspended in sterile 
4 mM HCI at 10 gg/ml and stored at -20°C. Cell numbers were determined 
using a Coulter Counter (Coulter Electronics Inc., Hialeah, FL) and were 
confirmed with a hemocytometer. To determine the extent of fusion, nuclei 
were counted visually in five randomly selected fields at a magnification of 
100. Cells containing >2 nuclei were considered to be fused. For metabolic 
labeling of proteins, cultures were incubated for 2  h  with L-[35S]methio- 
nine (New England Nuclear, Boston, MA; ,M,000 Ci/mmol) at 100 ixCi/ml 
in DME without methionine and containing 0.5 % FCS dialyzed against PBS 
(140 mM  NaCI,  10 mM  Na2HPO4,  pH 7.2).  At the end of the labeling 
period, extracts were prepared as described previously (27). 
Creatine Kinase and ACh Receptor Assays 
Creatine kinase was assayed as described previously (27).  ACh receptors 
were assayed by specific binding of [125I]a-bongarotoxin to cell monolayers 
as described (28,  29). 
Preparation of Total Cellular RNA 
Total cellular RNA was prepared from cultures according to a modification 
of the 8 M  guanidine HC1 procedure as described previously (27). 
Labeling cDNA Probes 
To quantitate steady-state levels of muscle isoenzyme of creatine kinase 
(MCK) mRNA, a SmaI-EcoRI restriction fragment was isolated from plas- 
mid R21  containing an insert homologous to canine MCK mRNA (33). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  mRNA was mea- 
sured using a  1,650-base  pair HhaI  restriction fragment isolated from a 
chicken GAPDH cDNA clone, pGAD-28 (5).  Inserts were labeled with 
32p to a specific activity of 1-5  x  109 cpm/~tg as described by Feinberg and 
Vogelstein (8). 
Northern Blot Hybridization 
Formaldehyde-agamse gel electmphoresis of RNA and Northern blot hy- 
bridization were performed as described previously (35).  Blots were ex- 
posed to Kodak XAR film at -70°C with DuPont Lightning-Plus intensify- 
ing screens (DuPont Co., Wilmington, DE). For quantitation of mRNAs, 
films were exposed for periods during which band intensity was linear with 
respect to time. Films were then scanned with a densitometer and mRNA 
abundance was determined from the area under the peak corresponding to 
individual mRNAs. Hybridization of cDNA probes to total cellular RNA 
was linear with respect to RNA concentration. 
IEF/SDS PAGE 
Two-dimensional gel electrophoresis of [35S]methionine-labeled  proteins 
was performed as described by O'Farrell (26). After staining and destaining, 
gels were treated with EN3HANCE (New England Nuclear) according to 
manufacturer's instructions. 
Results 
TGF~ Inhibits Myoblast Fusion and Appearance 
of  Muscle-specific Proteins 
C-2 cells proliferate rapidly in media with 20% FCS and do 
not express  the muscle phenotype.  Transfer  to media con- 
taining  insulin  and  transferrin  (fusion-promoting  media) 
results  in  withdrawal  of  cells  from  the  cell  cycle  within 
",24 h followed by fusion to form multinucleated myotubes 
over a period of ",3 d (Fig.  1). The process of fusion is ac- 
companied by induction of creatine kinase and the ACh re- 
ceptor (Fig.  2). 
To examine the possibility that TGFI3 might influence myo- 
genic differentiation, proliferating, undifferentiated C-2 cells 
were  exposed  to  fusion-promoting  media  with  TGFI3 (5 
ng/ml).  In the presence of TGFI~, C-2 cells withdrew from 
the cell cycle and achieved the same cell density as untreated 
cells (Fig. 2). However, cells treated with TGFI3 retained the 
bipolar morphology, characteristic of proliferating cells, and 
failed to fuse at the normal rate (Figs.  1 and 2). TGFI3 also 
delayed  induction of ACh receptor and creatine kinase for 
•48  h, after which, cultures began to fuse and differentiate 
Figure 1. Morphology of C-2 cells in the presence and absence of 
TGFI3.  C-2  cells were  cultured  in  DME  with  20%  FCS  as  de- 
scribed in Materials and Methods. To examine the effects of TGFI3, 
cultures  were  photographed  after  exposure  to  fusion-promoting 
media with or without TGFI3  (5  ng/ml)  for 3  d.  Conditions are 
identical to those on day  6  in Fig.  2. 
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Figure 2.  Effects on TGFI~ on differentiation of C-2 cells.  C-2 cells were cultured  in DME with 20%  serum as described  in Fig.  1. 
On each day, nuclei per dish (A) were counted,  the extent of fusion (B) was determined,  and ACh receptors  (C) and creatine  kinase 
activity (D) were measured.  On day 3, cultures were transferred  to fusion-promoting  media with or without TGFI3 (5 ng/ml).  On day 
7, TGFI3 was added to myotubes and was removed from TGFI3-treated cultures.  Fresh TGFI3 was added every 48 h to TGFI3-treated 
cultures.  Note that TGFI3 suppresses differentiation of mononucleated myoblasts and that differentiation proceeds at a normal rate after 
its removal. However, exposure of myotubes to TGFI3 has little or no effect on differentiation.  (e -  -  -  e) Control  cultures  without 
TGFI3; (O  O) cultures with TGFI3; (@--------e) myotubes exposed to TGF[~; (O .....  O) TGFI3-treated cultures exposed to fresh 
media without TGFI3. 
very slowly.  The low level of induction of muscle-specific 
proteins in the presence of TGFI3 was not due to toxicity or 
to inhibition of protein synthesis since rates of [35S]methio- 
nine  incorporation  into  protein  were  actually  increased 
slightly in the presence of TGFI3 (data not shown). Further- 
more, transfer of TGF[3-treated cultures to fresh media with- 
out TGFI3 resulted in fusion and induction of ACh receptors 
and creatine kinase with kinetics similar to those observed 
in untreated cultures (Fig.  2). 
We also examined the potential ability of TGFI3 to repress 
expression of muscle-specific gene products in myotubes. As 
shown in Fig. 2, exposure of myotubes to TGF[~ had little or 
no effect on expression of ACh receptor. In separate experi- 
ments,  it was found that creatine kinase also continued to 
be induced after the addition of TGFI3 to myotubes (Table I). 
Together,  these  results  demonstrate  that  TGF[~  inhibits 
differentiation of C-2 cells through a reversible mechanism 
that requires its continual presence in culture media. After 
fusion, C-2 cells become committed to terminal differentia- 
tion  and  lose  their  sensitivity  to  the  inhibitory  effects of 
TGFI3. Inhibition of differentiation by TGF[~ was not a sec- 
ondary consequence of cell proliferation because TGF[3 ex- 
hibited no mitogenic activity for C-2 cells (Fig.  2 A). 
Because of the pleiotropic actions of TGF[3 on different 
cell types, we were interested in whether the inhibitory ef- 
fects of this growth factor on myogenic differentiation were 
common to other muscle cell lines.  BC3H1 cells are a non- 
fusing cell line that has been shown to exhibit smooth muscle 
characteristics after differentiation in media containing 0.5 % 
serum (34,  36).  The effects of TGFI3  on proliferation and 
Table L TGF~ Fails to Block Induction of Creatine Kinase 
Activity in Myotubes 
Culture condition  Creatine kinase activity 
mlU/dish 
Day  6  -TGFI3  789 
Day  7  -  TGFI3  1,690 
Day  7  + TGFI3  1,430 
Conditions are identical to those on days 6 and 7  in Fig. 2.  Undifferentiated 
C-2  cells were  transferred to  fusion promoting media for  3  d  and creatine 
kinase activity was determined. Half of the remaining cultures were then ex- 
posed to TGFI3 (5 ng/ml) for  1 d and creatine kinase activity was determined 
in the treated and untreated cultures. Note that TGFI3  fails to block induction 
of creatine kinase in myotubes. 
differentiation of BC3H1 cells are shown in Fig. 3. Exposure 
of proliferating undifferentiated BC3H1 cells to 0.5 % serum 
containing TGFI3 (5  ng/ml) resulted in withdrawal of cells 
out of the cell cycle within 24 h. However, in contrast to con- 
trol cultures that acquire an elongated refractile appearance 
after growth  arrest (27, 34),  TGF~treated cultures  main- 
tained a flattened stellate morphology characteristic of un- 
differentiated cells (data not shown).  Cultures treated with 
TGF[3 also failed to differentiate at a normal rate as defined 
by expression  of ACh  receptor  and  creatine  kinase  (Fig. 
3).  While TGFI~ clearly inhibited differentiation of BC3H1 
cells, its effects were more complete in C-2 cells. The incom- 
plete inhibition of differentiation of BC3H1 cells was proba- 
bly due, at least in part, to depletion of TGFI3 from the me- 
dia, since daily additions of TGFI3 caused greater (although 
not total) repression (data not shown). As we observed for 
C-2 cells, inhibition of differentiation by TGFI3 was rapidly 
reversible after its removal from the culture media. 
To determine whether TGFI3 could inhibit expression of 
muscle-specific gene products in differentiated cells, quies- 
cent differentiated cultures were exposed to TGF[3. As shown 
in Fig. 3, TGFI3 caused a block in creatine kinase induction 
and a loss of ACh receptors from the cell surface at a rate 
equivalent to that reported previously for cultures exposed 
to media with 20%  serum (28,  29).  Thus, unlike C-2 myo- 
tubes which were refractory to "rGFI3, BC3H1 cells remained 
sensitive to the inhibitory effects of TGFI3 after differenti- 
ation. 
The dose dependence for repression of differentiation by 
TGFI3 was examined by transferring proliferating undifferen- 
tiated BC3H1 cells to media containing 0.5 % serum with or 
without TGFIt After 48 h, ACh receptors and creatine kinase 
activity were measured.  As shown in Fig.  4,  inhibition of 
differentiation could be observed at a TGFI3 concentration as 
low  as  0.20  ng/ml.  Half-maximal repression  occurred  at 
'~,0.5 ng/ml and maximal repression at '~1 ng/ml. 
Together, the data in Figs.  1-4 demonstrate that TGFI3 in- 
hibits expression of muscle-specific proteins in both C-2 and 
BC3HI cells through a  highly transient mechanism that is 
independent of cell proliferation. Inhibition of differentiation 
is not a general response to all growth factors because neither 
epidermal or platelet-derived growth factor had an apparent 
effect on expression of creatine kinase or ACh receptor (our 
unpublished results). 
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Figure 3.  Effects  of TGFI~ on differentiation of BC3H1 cells.  BC3HI cells  were cultured in DME with  20%  serum as described in 
Materials and Methods.  On each day, cells per dish (A) were counted and ACh receptors  (B) and creatine kinase activity (C) were mea- 
sured. On day 3, cultures were transferred to DME with 0.5% serum with or without TGFfl (5 ng/ml). On day 7, TGFl~-treated cultures 
were transferred to fresh media without TGFI3  and quiescent differentiated cultures were exposed to TGFI~ (5 ng/ml). Fresh TGFI3 was 
added every 48 h to TGFl~-treated cultures. Note that TGFI~ inhibits appearance  of muscle-specific  proteins and that after its removal, 
differentiation  proceeds  normally. Addition of TGFI~ to quiescent differentiated  cells also  blocks accumulation of muscle proteins. 
(e -  -  -  e) Control cultures without TGFI~; (O  O) cultures with TGFI3; (~-------~) quiescent, differentiated cultures exposed to 
TGFI3; (O .....  O) TGFl3-treated cultures exposed  to fresh  media without  TGFI3. 
TGFI3 Inhibits Accumulation of  MCK mRNA 
Previously we  reported that differentiation of BC3H1 cells 
was  accompanied by accumulation of MCK  mRNA.  Ex- 
posure of quiescent differentiated cells to media with 20 % 
serum or  fibroblast growth  factor resulted in a  decline in 
abundance of  MCK  mRNA  (35).  To  determine whether 
TGFI3 inhibited differentiation  through a mechanism similar 
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Figure 4.  Dose-dependent inhibition of differentiation of BC3HI 
cells  by  TGFI3.  BC3HI  cells  were  exposed  to  media  containing 
0.5%  serum for 2 d  with or without TGFI3 at the concentrations 
indicated  and  ACh  receptors  and  creatine  kinase  activity  were 
measured.  Values are expressed relative to control cultures with- 
out TGFI3  treatment,  which were  assigned a  value of  100%. 
to serum and fibroblast growth factor, steady-state levels of 
MCK mRNA were quantitated by Northern blot hybridiza- 
tion analysis.  As  shown  in Fig.  5,  exposure  of quiescent 
differentiated cells to TGFI3 or to media with 20%  serum 
resulted in a  dramatic decrease in the steady-state level of 
MCK mRNA.  This effect of TGFfl was specific for MCK 
mRNA as demonstrated by the lack of an effect on the steady- 
state level of GAPDH mRNA. Steady-state levels of GAPDH 
mRNA do not change in response to proliferation or differen- 
Figure 5.  TGFI3  specifically inhibits expression of MCK mRNA 
in BC3HI cells.  BC3H1 cells were allowed to differentiate  for 4 d 
in media with 0.5% serum. Cultures were then exposed to media 
containing 0.5 % serum with or without TGFI3 (5 ng/ml) or 20% 
serum, as specified. After 17 h, RNA was isolated and the relative 
abundance of MCK mRNA and GAPDH mRNA was determined 
by Northern blot hybridization. Note that TGFI3 and 20%  serum 
both cause a loss of MCK mRNA but have no effect on GAPDH 
mRNA. The position of 18 S ribosomal RNA is indicated. 
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gel electrophoresis of [35S]me- 
thionine-labeled proteins from 
BC3H1  cells  treated  with 
TGF[L  BC3H1 cells were  al- 
lowed to differentiate for 4  d 
in  media  with  0.5%  serum. 
Cultures  were  then  exposed 
to TGFI3 (5 ng/ml) for 28 h. 
Cultures under each condition 
were  labeled  with  [35S]me- 
thionine for  2  h  and labeled 
polypeptides  were  analyzed 
by  IEF/SDS  gel  electropho- 
resis as described in Materials 
and Methods. Major polypep- 
tides that change in abundance 
after  exposure  of  differen- 
tiated cells to TGFI3 are indi- 
cated with arrows. 
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TGFI3 can regulate myogenesis by specifically repressing 
muscle-specific mRNA accumulation. 
TGF~ Regulates Expression of  a Variety  of  Proteins 
in BC3H! Cells 
Because of the dramatic effects of TGFI3 on creatine kinase 
and ACh receptor, we were interested in determining wheth- 
er expression of other gene products also might be inhibited 
by TGFI3. To analyze the effects of TGFI3 on the pattern of 
protein synthesis, quiescent differentiated BCaH1 cells were 
exposed to TGFI3 for 28 h. Cultures were then labeled for 
2  h  with  [35S]methionine  and  labeled polypeptides  were 
separated by two-dimensional gel electrophoresis. As shown 
in Fig. 6,  10 proteins can be observed to decrease in abun- 
dance and '~6 proteins to increase in abundance after treat- 
ment of quiescent differentiated cells with TGFI3. Because 
only relatively abundant polypeptides are visualized on these 
gels, these represent minimum estimates of the total number 
of gene products whose expression is regulated by TGFI~ in 
these cells. The identities of the proteins that are down regu- 
lated by TGFI3 are currently unknown, but it seems likely 
some may represent  muscle-specific gene products  since 
they are regulated in parallel with creatine kinase and ACh 
receptor. 
Discussion 
During myogenesis, myoblasts cease dividing before activa- 
tion of muscle-specific genes (4, 6, 7, 9, 10, 13, 14, 16-18, 24, 
25, 27-30,  35).  While serum components clearly play a key 
role controlling the onset of myogenic differentiation, the 
identities and mechanisms of action of the specific growth 
factors that regulate this process are only beginning to be un- 
derstood. The characteristics of  the quiescent state that allow 
muscle-specific gene expression also remain unclear. 
The results of the present study demonstrate that TGFI3 is 
a potent regulator of myogenesis that specifically inhibits one 
or more steps  leading to activation of muscle-specific gene 
expression in both smooth muscle-like and skeletal muscle 
cells. Because TGFI3 was not mitogenic for either muscle cell 
type, this growth factor appears to interfere directly with the 
differentiation program and does not seem to influence dif- 
ferentiation as a secondary consequence of  cell proliferation. 
In this respect,  TGFI3 resembles the pituitary-derived and 
brain-derived fibroblast growth factors and a protein isolated 
from Buffalo rat liver, referred to as "differentiation inhibi- 
tor" or DI, each of  which have been shown to inhibit myogen- 
esis through a mechanism independent of cell proliferation 
(7,  13,  14, 35).  TGFI3 and the fibroblast growth factors are 
clearly distinct molecules; however, the relationship, if any, 
between TGFI3 and DI, remains to be determined. 
TGF[3 did not affect the rate at which C-2 cells stopped 
dividing  when  switched  into  fusion-promoting  medium. 
However, TGFI3 inhibited fusion and appearance of muscle- 
specific gene products almost completely for at least 4 d, de- 
spite the fact that cells were in a quiescent state (Fig. 2). 
Thus, simply prolonging G1 is not sufficient to induce dif- 
ferentiation. Previous studies have shown that myogenic dif- 
ferentiation occurs early in G1 and that cells arrested in late 
G1 fail to differentiate (4,  14). Moreover, fibroblast growth 
factor causes transit of quiescent BC3HI cells to a restric- 
tion point 4-6 h into G1, that is nonpermissive for differen- 
tiation (14). We do not know yet whether TGFI3 inhibits myo- 
genesis by causing quiescent myoblasts to progress to this 
later region of G~. We also do not presently know whether 
TGFI3  directly  represses  transcription  of muscle-specific 
genes or alternatively, leads to a generalized metabolic state 
that is incompatible with expression of this set of genes. 
Removal  of TGFI~ from quiescent undifferentiated C-2 
or BC3HI cells, allowed the appearance of muscle-specific 
proteins at a normal rate with no apparent lag, which sug- 
gests that the inhibitory signals generated by TGFI3 are tran- 
sient and require continuous occupancy of the TGFI3 recep- 
tor. After fusion, C-2 cells became refractory to the effects 
of TGFI3 while BC3H1 cells remained sensitive to TGFI3 in- 
dependent of their state of differentiation. Whether the in- 
ability of TGFI3 to reverse the differentiation  process in myo- 
tubes is due to a loss of TGFI3 receptors, as has been reported 
for EGF receptors during differentiation of mouse MMI4 
myoblasts (16), or is due to some other alteration has not been 
determined. 
In addition to inhibiting expression of creatine kinase and 
ACh receptor, TGFI3 also decreased the synthesis of at least 
10 relatively abundant polypeptides in BC3HI cells (Fig. 6). 
The identifies of these proteins are currently unknown. How- 
ever, they may represent other muscle-specific gene products 
that are subject to coordinate regulation by TGFI3. A set of 
polypepfides also was induced in BC3H1 cells by TGFI3. Re- 
cent studies by Leof et al. (15) suggest that at least some of 
these polypeptides may belong to the  "competence" gene 
family, which is induced by platelet-derived growth factor 
during the transition of from quiescence to proliferation (3). 
Using AKR-2B cells, these investigators reported that TGFI3 
caused  induction  of  c-sis  and  the  subsequent  induction 
of c-fos,  c-myc, and other PDGF-inducible gene products 
through an autocrine mechanism (15). Identification of the 
polypepfides that are up and down regulated by TGFI3 in 
BC3H1 cells may help reveal the mechanisms through which 
this growth factor represses myogenic differentiation. Since 
many polypepfides are regulated by TGFI3 in BC3H1 cells, 
this will be an interesting system for studies on regulation of 
gene expression by this growth factor. 
Little is known of the mechanisms involved in signal trans- 
duction by TGFI~. Tyrosine protein  kinase activity, com- 
monly associated with growth factor receptors, has not yet 
been demonstrated for the TGFI3 receptor, nor have other po- 
tential signaling mechanisms been identified. The similari- 
ties between the effects of TGFfl,  fibroblast growth factor, 
and DI on myogenesis suggest that these growth factors may 
share a  common postreceptor pathway.  Currently, we are 
attempting to  identify possible  intracellular  second  mes- 
sengers that may mediate the effects of TGFI3 and fibroblast 
growth factor on differentiation. 
The physiological significance of TGFI3 as an inhibitor of 
myogenesis remains to be determined. TGFI3 might be in- 
volved in regulating the timing of myoblast fusion during 
early embryonic development. TGFI3 might also be respon- 
sible for maintenance of satellite cells, the mononucleated 
myoblasts that surround mature muscle fibers.  Combined 
with previous studies, the results presented here suggest that 
TGFI3 plays an important role in regulation of tissue-specific 
gene expression during early development. It will be espe- 
The Journal of Cell Biology, Volume 103, 1986  1804 cially interesting to determine whether TGFI3 interacts with 
common regulatory pathways in diverse cell types to control 
proliferation and differentiation. 
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